Canandaigua National Trust Co of Florida Makes New Investment in Johnson & Johnson $JNJ

Canandaigua National Trust Co of Florida purchased a new position in Johnson & Johnson (NYSE:JNJ) in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 3,496 shares of the company’s stock, valued at approximately $926,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after acquiring an additional 2,513,321 shares in the last quarter. Deutsche Bank AG raised its position in shares of Johnson & Johnson by 8.5% in the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after purchasing an additional 1,225,676 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Johnson & Johnson by 8.7% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 17,275,937 shares of the company’s stock valued at $3,575,255,000 after buying an additional 1,376,828 shares during the last quarter. Amundi raised its holdings in Johnson & Johnson by 17.5% in the first quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares in the last quarter. Finally, Nuveen LLC boosted its stake in Johnson & Johnson by 6.9% during the 4th quarter. Nuveen LLC now owns 10,609,171 shares of the company’s stock valued at $2,195,568,000 after acquiring an additional 683,967 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

Shares of JNJ traded up $3.47 during midday trading on Wednesday, hitting $258.25. 5,394,094 shares of the stock traded hands, compared to its average volume of 7,981,786. The business’s 50 day moving average price is $265.86 and its two-hundred day moving average price is $248.63. The firm has a market capitalization of $622.35 billion, a PE ratio of 29.92, a price-to-earnings-growth ratio of 2.48 and a beta of 0.21. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09. Johnson & Johnson has a 1-year low of $184.66 and a 1-year high of $281.07.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. The business had revenue of $25.31 billion for the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The company’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Equities research analysts predict that Johnson & Johnson will post 11.54 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 8th. Stockholders of record on Tuesday, August 25th were issued a dividend of $1.34 per share. This represents a $5.36 dividend on an annualized basis and a dividend yield of 2.1%. The ex-dividend date of this dividend was Tuesday, August 25th. Johnson & Johnson’s payout ratio is 62.11%.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. TD Cowen increased their price target on shares of Johnson & Johnson from $250.00 to $300.00 and gave the stock a “buy” rating in a research report on Monday, July 13th. Weiss Ratings raised Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday, July 24th. Johnson Rice reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Monday, August 3rd. HSBC lifted their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Stifel Nicolaus set a $260.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, July 15th. One analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $276.22.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analyst support: Guggenheim reaffirmed its “Buy” rating and set a $287 price target, implying further upside from recent trading levels. RBC Capital Markets has also maintained its “Buy” rating. RBC Capital Keeps Their Buy Rating on Johnson & Johnson
• Positive Sentiment: Pipeline progress: Johnson & Johnson reported that the Tecvayli-Talvey combination reduced the relative risk of disease progression or death by 89% and the risk of death by 62% in relapsed or refractory multiple myeloma. The results support potential expansion of the company’s oncology franchise. 2026 Cancer Treatment Advances
• Positive Sentiment: Two-year Phase 3 data for oral psoriasis treatment ICOTYDE showed sustained skin clearance and consistent safety through Week 112, potentially adding another growth product to the Innovative Medicines portfolio. ICOTYDE Long-Term Psoriasis Data
• Positive Sentiment: Recent quarterly results showed 6.6% revenue growth, adjusted EPS above consensus and increased 2026 guidance, reinforcing the view that J&J may be developing into more than a purely defensive healthcare stock. Johnson & Johnson Is Becoming a Growth Stock
• Neutral Sentiment: J&J’s 64-year record of dividend increases continues to attract income investors, although the stock’s valuation means investors are paying for part of that quality and expected growth.
• Negative Sentiment: Investors remain concerned about upcoming patent and biosimilar pressure, a slower MedTech recovery, and ongoing talc litigation. These issues could limit earnings growth and offset strength in Innovative Medicines. Johnson & Johnson Dividend and Risk Analysis

Insiders Place Their Bets

In other news, EVP Jennifer L. Taubert sold 15,000 shares of the firm’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president directly owned 194,451 shares of the company’s stock, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 87,569 shares of company stock valued at $23,064,544. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Profile

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets products through two primary business segments: Innovative Medicine and MedTech. Its operations serve patients, healthcare professionals and consumers in markets around the world.

The Innovative Medicine segment focuses on prescription medicines in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.